Welcome to our dedicated page for Allogene Therapeutics news (Ticker: $ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allogene Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allogene Therapeutics's position in the market.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report first quarter 2024 financial results and provide a business update on May 13, 2024. The company specializes in allogeneic CAR T products for cancer and autoimmune disease. A live audio webcast and conference call will follow the announcement.
Allogene Therapeutics has been awarded a $15 million grant from the California Institute for Regenerative Medicine to advance the development of ALLO-316, an AlloCAR T™ product targeting CD70 for the treatment of advanced or metastatic renal cell carcinoma. The grant supports the Phase 1 TRAVERSE trial, showing promising early anti-tumor activity and deepening responses over time in participants with advanced RCC. ALLO-316 utilizes Dagger® technology to optimize CAR T cell expansion and persistence, potentially revolutionizing solid tumor treatment.